US20140234228A1 - Effervescent compositions containing n-acetylcysteine - Google Patents

Effervescent compositions containing n-acetylcysteine Download PDF

Info

Publication number
US20140234228A1
US20140234228A1 US14/264,444 US201414264444A US2014234228A1 US 20140234228 A1 US20140234228 A1 US 20140234228A1 US 201414264444 A US201414264444 A US 201414264444A US 2014234228 A1 US2014234228 A1 US 2014234228A1
Authority
US
United States
Prior art keywords
effervescent composition
composition according
nac
carbonate
acetylcysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/264,444
Inventor
Federico Stroppolo
Gabriele GRANATA
Shahbaz S. Ardalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpex Pharma SA
Original Assignee
Alpex Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpex Pharma SA filed Critical Alpex Pharma SA
Priority to US14/264,444 priority Critical patent/US20140234228A1/en
Assigned to ALPEX PHARMA S.A. reassignment ALPEX PHARMA S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Granata, Gabriele, SHAHBAZ, ARDALAN, STROPPOLO, FEDERICO
Publication of US20140234228A1 publication Critical patent/US20140234228A1/en
Assigned to ALPEX PHARMA S.A. reassignment ALPEX PHARMA S.A. CORRECTIVE ASSIGNMENT TO CORRECT THE THE NAME OF THE THIRD INVENTOR PREVIOUSLY RECORDED ON REEL 032784 FRAME 0949. ASSIGNOR(S) HEREBY CONFIRMS THE THE CORRECT NAME IS SHAHBAZ S. ARDALAN. Assignors: ARDALAN, SHAHBAZ S., Granata, Gabriele, STROPPOLO, FEDERICO
Priority to US14/800,228 priority patent/US9427421B2/en
Priority to US15/222,232 priority patent/US9561204B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Definitions

  • the present invention relates to effervescent pharmaceutical compositions containing N-acetylcysteine, more particularly to effervescent compositions containing a high amount of N-acetylcysteine useful for the oral treatment of acetaminophen poisoning.
  • N-acetylcysteine is a well-known drug approved worldwide for several indications mainly as mucolytic agent but it is also one of the few available treatments for acetaminophen poisoning.
  • Acetaminophen (paracetamol) is a commonly used analgesic and antipyretic drug. Accidental or suicidal acetaminophen overdose can cause severe liver damage which result in several deaths each year in the U.S.A.
  • NAC is effective by intravenous or oral route for the treatment of acetaminophen poisoning if administered within 8-10 hours of acetaminophen overdose.
  • the dose of NAC to be administered is very high according to the Prescott therapy protocol, as reported in the following table 1:
  • NAC NAC Body weight loading dose maintenance dose (kg) (g) (g) 100-109 15 7.5 90-99 14 7 80-89 13 6.5 70-79 11 5.5 60-69 10 5 50-59 8 4 40-49 7 3.5 30-39 6 3 20-29 4 2
  • NAC dosage form for the treatment of acetaminophen poisoning is Acetadote®, 30 ml vials containing 200 mg/ml NAC for intravenous administration.
  • acetaminophen poisoning with NAC is equally or even more effective than intravenous treatment when administered within 8-10 hours of acetaminophen overdose (Michele Zell Kanter, American Journal of Health—System Pharmacy, Oct. 1, 2006 vol. 63 no. 19, 1821-1827), the contents of which are incorporated herein by reference and would be more practical and safer.
  • the very high dosage limits the possibility to use commercially available NAC formulations for oral administration which usually have a maximum NAC content of 600 mg.
  • the present invention relates to an effervescent composition containing at least 50% w/w of NAC, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent.
  • the present invention relates to a method of treating acetaminophen poisoning.
  • the method includes administering an effective amount of an effervescent composition containing at least 50% w/w of NAC, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent to a patient in need of such treatment.
  • the present invention relates to an effervescent composition containing a high amount of NAC which is particularly useful for the oral treatment of acetaminophen poisoning.
  • the effervescent composition and object of the present invention contains at least 50% w/w of NAC, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent.
  • a value % w/w means the weight per cent of a component of the composition with respect to the total weight of said composition.
  • the amount of NAC in the effervescent composition ranges from 50% to 80% w/w, more preferably, it is from 50% to 60% w/w.
  • the amount of NAC is about 54-55% w/w.
  • Suitable carbonate or bicarbonate salts are pharmaceutically acceptable carbonate or bicarbonate salts commonly used as CO 2 source in effervescent compositions.
  • Specific examples include sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate (NaHCO 3 +Na 2 CO 3 +2H 2 O), sodium glycine carbonate and the like.
  • Sodium bicarbonate is particularly preferred.
  • the amount of carbonate or bicarbonate salt in the effervescent compositions according to the present invention is at least 20% w/w, preferably from 20% to 45% w/w, and more preferably from 30% to 35% w/w.
  • the Applicant has found that the formulation of the present invention develops effervescence in water without the need of an additional organic or inorganic acid, making it particularly advantageous in comparison with known effervescent NAC compositions which require the presence of an effervescent couple.
  • the effervescent composition of the present invention usually contains a mixture of excipients comprising a sweetener, a flavor, and a diluent.
  • the total amount of the additional excipients is usually from 3.5% to 15% w/w.
  • Suitable sweeteners include sugars, such as mono- or di-saccharides, for example glucose, saccharose, maltose, galactose, and artificial sweeteners, such as sodium saccharin, acesulfame potassium, cyclamates, sucralose. Artificial sweeteners are preferred, and among them sucralose is particularly preferred.
  • the amount of sweetener ranges from 0.2% to 10% w/w, and preferably is from 0.5% to 1% w/w.
  • the amount of flavor ranges from 1% to 3% w/w, and preferably is about 2% w/w.
  • Any pharmaceutically acceptable flavors can be used such as fruit flavor, peppermint flavor, etc. Fruit flavors are preferred, and lemon and orange flavors are particularly preferred.
  • Suitable diluents include polyols, such as for example mannitol, sorbitol, xylitol, as well as cellulose, starch and maltodextrin.
  • Maltodextrin is particularly preferred.
  • the amount of diluent usually ranges from 2% to 20% w/w.
  • the effervescent composition according to the present invention can optionally contain further pharmaceutically acceptable excipients such as chelating agents, for example EDTA, lubricants, for example sodium benzoate and magnesium stearate, colorants, etc.
  • chelating agents for example EDTA
  • lubricants for example sodium benzoate and magnesium stearate, colorants, etc.
  • the amount of lubricant usually ranges from 0.1% to 5% w/w.
  • Sodium benzoate is preferably used.
  • the effervescent NAC compositions of the invention are prepared by conventional granulation techniques, preferably by wet granulation for example in a fluid bed granulator.
  • the effervescent granulate can be used as such as finished dosage form, for example filled in sachets or can be compressed into tablets.
  • the pharmaceutical NAC composition according to the invention is in the form of effervescent tablets.
  • the dose of NAC contained in the finished dosage unit can range from 0.5 g to 2.5 g without changing the physical properties of the solid composition.
  • the effervescent formulations according to the present invention are readily soluble in a small amount of water, have a good taste and are of limited dimensions to be easily stored and transported.
  • the unit dose of NAC can be for example 0.5 g, 1.0 g, 1.5 g, 2.0 g and 2.5 g. Unit doses of 0.5 g and 2.5 g are particularly preferred because they can be easy combined to reach any therapeutic dose required by the Prescott therapy protocol as reported in the following table 2.
  • the high content of NAC of the compositions together with their very high solubility results in the possibility to easy adjust the administered dose according to the therapy protocol by calculating the number of tablets (as multiple of the 2.5 g dose and/or as multiple of the 0.5 g dose) and to dissolve it into a glass of water.
  • the resultant solution contains the therapeutic dose of NAC, has a good taste, is very easy to administer to the patient.
  • the required therapeutic dose is very easy to calculate in terms of number of tablets or sachets to dissolve.
  • the glass of water containing a therapeutic dose of NAC has a good taste (good patient compliance also in case of children) and does not require trained nurses to be administered, as in the case of NAC vials.
  • NAC sodium bicarbonate (348 g), maltodextrin (79.8 g), sucralose (7 g), and EDTA sodium (0.2 g) were granulated together with water in a fluid bed granulator.
  • the granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with sodium benzoate (3 g) and orange flavor (19 g).
  • the resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
  • NAC sodium bicarbonate (348.2 g), maltodextrin (79.8 g), and sucralose (7 g) were granulated together with water in a fluid bed granulator.
  • the granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with sodium benzoate (3 g) and orange flavor (19 g).
  • the resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
  • NAC sodium bicarbonate (351 g), maltodextrin (79.8 g), sucralose (7 g), and EDTA sodium (0.2 g) were granulated together with water in a fluid bed granulator.
  • the granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • the resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
  • NAC sodium bicarbonate (351.2 g), maltodextrin (79.8 g), and sucralose (7 g), were granulated together with water in a fluid bed granulator.
  • the granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • the resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
  • NAC sodium bicarbonate (351 g), maltodextrin (79.8 g), sucralose (7 g), and EDTA sodium (0.2 g) were granulated together with water in a fluid bed granulator.
  • the granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • the resultant mixture was filled into paper/aluminum sachets, 40 ⁇ 60 mm, weighing 4.6 g and containing 2.5 g NAC or weighing 0.92 g and containing 0.5 g NAC.
  • NAC sodium bicarbonate (351.2 g), maltodextrin (79.8 g), and sucralose (7 g) were granulated together with water in a fluid bed granulator.
  • the granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • the resultant mixture was filled into paper/aluminum sachets, 40 ⁇ 60 mm, weighing 4.6 g and containing 2.5 g NAC or weighing 0.92 g and containing 0.5 g NAC.

Abstract

Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 13/466,721 filed May 8, 2012, the contents of which is incorporated herein by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to effervescent pharmaceutical compositions containing N-acetylcysteine, more particularly to effervescent compositions containing a high amount of N-acetylcysteine useful for the oral treatment of acetaminophen poisoning.
    • BACKGROUND OF THE INVENTION
  • N-acetylcysteine (NAC) is a well-known drug approved worldwide for several indications mainly as mucolytic agent but it is also one of the few available treatments for acetaminophen poisoning.
  • Acetaminophen (paracetamol) is a commonly used analgesic and antipyretic drug. Accidental or suicidal acetaminophen overdose can cause severe liver damage which result in several deaths each year in the U.S.A.
  • NAC is effective by intravenous or oral route for the treatment of acetaminophen poisoning if administered within 8-10 hours of acetaminophen overdose. The dose of NAC to be administered is very high according to the Prescott therapy protocol, as reported in the following table 1:
  • TABLE 1
    NAC doses according to the Prescott therapy protocol
    NAC NAC
    Body weight loading dose maintenance dose
    (kg) (g) (g)
    100-109 15 7.5
    90-99 14 7
    80-89 13 6.5
    70-79 11 5.5
    60-69 10 5
    50-59 8 4
    40-49 7 3.5
    30-39 6 3
    20-29 4 2
  • The only available NAC dosage form for the treatment of acetaminophen poisoning is Acetadote®, 30 ml vials containing 200 mg/ml NAC for intravenous administration.
  • The oral treatment of acetaminophen poisoning with NAC is equally or even more effective than intravenous treatment when administered within 8-10 hours of acetaminophen overdose (Michele Zell Kanter, American Journal of Health—System Pharmacy, Oct. 1, 2006 vol. 63 no. 19, 1821-1827), the contents of which are incorporated herein by reference and would be more practical and safer. However, the very high dosage limits the possibility to use commercially available NAC formulations for oral administration which usually have a maximum NAC content of 600 mg.
  • Therefore, it would be desirable to have an oral formulation containing a high amount of NAC to be used for the treatment of acetaminophen poisoning.
    • SUMMARY OF THE INVENTION
  • We have now found an effervescent composition containing a high amount of NAC which is very easy to administer as an aqueous solution and is particularly useful for the oral treatment of acetaminophen poisoning.
  • In a first aspect, the present invention relates to an effervescent composition containing at least 50% w/w of NAC, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent.
  • In a further aspect, the present invention relates to a method of treating acetaminophen poisoning. The method includes administering an effective amount of an effervescent composition containing at least 50% w/w of NAC, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent to a patient in need of such treatment.
    • DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION
  • The present invention relates to an effervescent composition containing a high amount of NAC which is particularly useful for the oral treatment of acetaminophen poisoning.
  • The effervescent composition and object of the present invention contains at least 50% w/w of NAC, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent.
  • As used herein, a value % w/w means the weight per cent of a component of the composition with respect to the total weight of said composition.
  • In a preferred embodiment, the amount of NAC in the effervescent composition ranges from 50% to 80% w/w, more preferably, it is from 50% to 60% w/w.
  • In a particularly preferred embodiment of the present invention, the amount of NAC is about 54-55% w/w.
  • Suitable carbonate or bicarbonate salts are pharmaceutically acceptable carbonate or bicarbonate salts commonly used as CO2 source in effervescent compositions.
  • Specific examples include sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate (NaHCO3+Na2CO3+2H2O), sodium glycine carbonate and the like.
  • Sodium bicarbonate is particularly preferred.
  • The amount of carbonate or bicarbonate salt in the effervescent compositions according to the present invention is at least 20% w/w, preferably from 20% to 45% w/w, and more preferably from 30% to 35% w/w.
  • The Applicant has found that the formulation of the present invention develops effervescence in water without the need of an additional organic or inorganic acid, making it particularly advantageous in comparison with known effervescent NAC compositions which require the presence of an effervescent couple.
  • In addition to the active ingredient and the carbonate or bicarbonate salt, the effervescent composition of the present invention usually contains a mixture of excipients comprising a sweetener, a flavor, and a diluent.
  • The total amount of the additional excipients is usually from 3.5% to 15% w/w.
  • Suitable sweeteners include sugars, such as mono- or di-saccharides, for example glucose, saccharose, maltose, galactose, and artificial sweeteners, such as sodium saccharin, acesulfame potassium, cyclamates, sucralose. Artificial sweeteners are preferred, and among them sucralose is particularly preferred.
  • The amount of sweetener ranges from 0.2% to 10% w/w, and preferably is from 0.5% to 1% w/w.
  • The amount of flavor ranges from 1% to 3% w/w, and preferably is about 2% w/w.
  • Any pharmaceutically acceptable flavors can be used such as fruit flavor, peppermint flavor, etc. Fruit flavors are preferred, and lemon and orange flavors are particularly preferred.
  • Suitable diluents include polyols, such as for example mannitol, sorbitol, xylitol, as well as cellulose, starch and maltodextrin.
  • Maltodextrin is particularly preferred.
  • The amount of diluent usually ranges from 2% to 20% w/w.
  • The effervescent composition according to the present invention can optionally contain further pharmaceutically acceptable excipients such as chelating agents, for example EDTA, lubricants, for example sodium benzoate and magnesium stearate, colorants, etc.
  • When a lubricant is present in the formulation according to the present invention, the amount of lubricant usually ranges from 0.1% to 5% w/w.
  • Sodium benzoate is preferably used.
  • The effervescent NAC compositions of the invention are prepared by conventional granulation techniques, preferably by wet granulation for example in a fluid bed granulator.
  • The effervescent granulate can be used as such as finished dosage form, for example filled in sachets or can be compressed into tablets.
  • In a preferred embodiment, the pharmaceutical NAC composition according to the invention is in the form of effervescent tablets.
  • The dose of NAC contained in the finished dosage unit can range from 0.5 g to 2.5 g without changing the physical properties of the solid composition.
  • In particular, the effervescent formulations according to the present invention are readily soluble in a small amount of water, have a good taste and are of limited dimensions to be easily stored and transported.
  • The unit dose of NAC can be for example 0.5 g, 1.0 g, 1.5 g, 2.0 g and 2.5 g. Unit doses of 0.5 g and 2.5 g are particularly preferred because they can be easy combined to reach any therapeutic dose required by the Prescott therapy protocol as reported in the following table 2.
  • TABLE 2
    Number of Number of Volume of
    tablets of the tablets of the reconstituted
    Body invention invention solution to be
    weight NAC (2.5 g (0.5 g administered to
    (Kg) (g) NAC/tablet) NAC/tablet) patients
    Loading dose
    100-109 15 6 0 About 200 mL
    90-99 14 5 3 (a glass of water)
    80-89 13 5 1
    70-79 11 4 2
    60-69 10 4 0
    50-59 8 3 1
    40-49 7 2 4
    30-39 6 2 2
    20-29 4 1 3
    Maintenance dose
    100-109 7.5 3 0 About 200 mL
    90-99 7 2 4 (a glass of water)
    80-89 6.5 2 3
    70-79 5.5 2 1
    60-69 5 2 0
    50-59 4 1 3
    40-49 3.5 1 2
    30-39 3 1 1
    20-29 2 0 4
  • The above table clearly shows some of the most significant advantages of the effervescent composition of the present invention in the treatment of acetaminophen poisoning.
  • The high content of NAC of the compositions together with their very high solubility results in the possibility to easy adjust the administered dose according to the therapy protocol by calculating the number of tablets (as multiple of the 2.5 g dose and/or as multiple of the 0.5 g dose) and to dissolve it into a glass of water.
  • The resultant solution contains the therapeutic dose of NAC, has a good taste, is very easy to administer to the patient.
  • The possibility to administer the effervescent compositions of the invention in a glass of water is a remarkable advantage over the commercially available NAC formulations used for the treatment of acetaminophen poisoning.
  • The required therapeutic dose is very easy to calculate in terms of number of tablets or sachets to dissolve.
  • The glass of water containing a therapeutic dose of NAC has a good taste (good patient compliance also in case of children) and does not require trained nurses to be administered, as in the case of NAC vials.
  • The following examples better illustrate the present invention without limiting it.
    • EXAMPLE 1
  • NAC (543 g), sodium bicarbonate (348 g), maltodextrin (79.8 g), sucralose (7 g), and EDTA sodium (0.2 g) were granulated together with water in a fluid bed granulator.
  • The granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with sodium benzoate (3 g) and orange flavor (19 g).
  • The resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
    • EXAMPLE 2
  • NAC (543 g), sodium bicarbonate (348.2 g), maltodextrin (79.8 g), and sucralose (7 g) were granulated together with water in a fluid bed granulator.
  • The granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with sodium benzoate (3 g) and orange flavor (19 g).
  • The resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
    • EXAMPLE 3
  • NAC (543 g), sodium bicarbonate (351 g), maltodextrin (79.8 g), sucralose (7 g), and EDTA sodium (0.2 g) were granulated together with water in a fluid bed granulator.
  • The granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • The resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
    • EXAMPLE 4
  • NAC (543 g), sodium bicarbonate (351.2 g), maltodextrin (79.8 g), and sucralose (7 g), were granulated together with water in a fluid bed granulator.
  • The granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • The resultant mixture was compressed into flat round tablets, 25 mm diameter, weighing 4.6 g and containing 2.5 g NAC or into flat round tablets, 14 mm diameter, weighing 0.92 g and containing 0.5 g NAC.
    • EXAMPLE 5
  • NAC (543 g), sodium bicarbonate (351 g), maltodextrin (79.8 g), sucralose (7 g), and EDTA sodium (0.2 g) were granulated together with water in a fluid bed granulator.
  • The granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • The resultant mixture was filled into paper/aluminum sachets, 40×60 mm, weighing 4.6 g and containing 2.5 g NAC or weighing 0.92 g and containing 0.5 g NAC.
    • EXAMPLE 6
  • NAC (543 g), sodium bicarbonate (351.2 g), maltodextrin (79.8 g), and sucralose (7 g) were granulated together with water in a fluid bed granulator.
  • The granulate was then dried until a residual moisture content of not more than 0.5%, unloaded from the fluid bed and blended with orange flavor (19 g).
  • The resultant mixture was filled into paper/aluminum sachets, 40×60 mm, weighing 4.6 g and containing 2.5 g NAC or weighing 0.92 g and containing 0.5 g NAC.

Claims (18)

What is claimed is:
1. An effervescent composition comprising at least 50% w/w of N-acetylcysteine, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent.
2. The effervescent composition according to claim 1 wherein the amount of N-acetylcysteine is from 50% to 80% w/w.
3. The effervescent composition according to claim 2 wherein the amount of N-acetylcysteine is from 50% to 60% w/w.
4. The effervescent composition according to claim 3 wherein the amount of N-acetylcysteine is about 54-55% w/w.
5. The effervescent composition according to claim 1 wherein the carbonate or bicarbonate salt is selected from the group consisting of sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate.
6. The effervescent composition according to claim 5 wherein the bicarbonate salt is sodium bicarbonate.
7. The effervescent composition according to claim 1 wherein the amount of carbonate or bicarbonate salt is from 20% to 45% w/w.
8. The effervescent composition according to claim 7 wherein the amount of carbonate or bicarbonate salt is from 30% to 35% w/w.
9. The effervescent composition according to claim 1 wherein the sweetener is selected from the group consisting of sugars and artificial sweeteners.
10. The effervescent composition according to claim 9 wherein the artificial sweetener is selected from the group consisting of sodium saccharin, acesulfame potassium, cyclamates, sucralose.
11. The effervescent composition according to claim 10 wherein the artificial sweetener is sucralose.
12. The effervescent composition according to claim 1 wherein the diluent is selected from the group consisting of polyols, cellulose, starch and maltodextrin.
13. The effervescent composition according to claim 12 wherein the diluent is maltodextrin.
14. The effervescent composition according to claim 1 further comprising a lubricant.
15. The effervescent composition according to claim 14 wherein the lubricant is sodium benzoate.
16. A method of treating acetaminophen poisoning, comprising administering an effective amount of effervescent composition containing at least 50% w/w of N-acetylcysteine, at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener, a flavor, and a diluent to a patient in need thereof.
17. The method according to claim 16 wherein the effervescent composition contains a unit-dose of N-acetylcysteine of 0.5 g, 1.0 g, 1.5 g, 2.0 g, 2.5 g and combinations thereof.
18. The method according to claim 17 wherein the unit-dose is 0.5 g, 2.5 g and combinations thereof.
US14/264,444 2012-05-08 2014-04-29 Effervescent compositions containing n-acetylcysteine Abandoned US20140234228A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/264,444 US20140234228A1 (en) 2012-05-08 2014-04-29 Effervescent compositions containing n-acetylcysteine
US14/800,228 US9427421B2 (en) 2012-05-08 2015-07-15 Effervescent compositions containing N-acetylcysteine
US15/222,232 US9561204B2 (en) 2012-05-08 2016-07-28 Effervescent compositions containing N-acetylcysteine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/466,721 US8747894B2 (en) 2012-05-08 2012-05-08 Effervescent compositions containing N-acetylcysteine
US14/264,444 US20140234228A1 (en) 2012-05-08 2014-04-29 Effervescent compositions containing n-acetylcysteine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/466,721 Continuation US8747894B2 (en) 2012-05-08 2012-05-08 Effervescent compositions containing N-acetylcysteine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/800,228 Continuation US9427421B2 (en) 2012-05-08 2015-07-15 Effervescent compositions containing N-acetylcysteine

Publications (1)

Publication Number Publication Date
US20140234228A1 true US20140234228A1 (en) 2014-08-21

Family

ID=48190334

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/466,721 Active US8747894B2 (en) 2012-05-08 2012-05-08 Effervescent compositions containing N-acetylcysteine
US14/264,444 Abandoned US20140234228A1 (en) 2012-05-08 2014-04-29 Effervescent compositions containing n-acetylcysteine
US14/800,228 Active US9427421B2 (en) 2012-05-08 2015-07-15 Effervescent compositions containing N-acetylcysteine
US15/222,232 Active US9561204B2 (en) 2012-05-08 2016-07-28 Effervescent compositions containing N-acetylcysteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/466,721 Active US8747894B2 (en) 2012-05-08 2012-05-08 Effervescent compositions containing N-acetylcysteine

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/800,228 Active US9427421B2 (en) 2012-05-08 2015-07-15 Effervescent compositions containing N-acetylcysteine
US15/222,232 Active US9561204B2 (en) 2012-05-08 2016-07-28 Effervescent compositions containing N-acetylcysteine

Country Status (2)

Country Link
US (4) US8747894B2 (en)
EP (1) EP2662077B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117987A1 (en) 2014-02-05 2015-08-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Effervescent formulations comprising ibuprofen and n-acetylcystein
CN104758269A (en) * 2015-02-12 2015-07-08 北京众盈汇丰科技发展有限责任公司 Acetylcysteine effervescent tablet
JP7074663B6 (en) 2015-05-28 2022-08-01 ベイラー カレッジ オブ メディスン Effects of N-Acetylcysteine and Glycine Supplementation to Improve Glutathione Levels
FR3047898B1 (en) * 2016-02-23 2020-09-18 Alpex Pharma NON-EFFERVESCENT GRANULES CONTAINING N-ACETYLCYSTEINE.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667590A5 (en) * 1986-07-24 1988-10-31 Inpharzam Int Sa WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. .
US6719969B1 (en) 1999-08-09 2004-04-13 The Regents Of The University Of Michigan Treatment of liver disease and injury with CXC chemokines
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
TR200900882A2 (en) * 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Pharmaceutical compositions with high bioavailability, masked by taste and odor.
TR200900881A2 (en) * 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Stable pharmaceutical compositions masked by taste and odor
CN105687177A (en) * 2009-07-15 2016-06-22 小利兰·斯坦福大学托管委员会 N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
IT1399492B1 (en) * 2010-04-13 2013-04-19 Alpex Pharma Sa EFFERVESCENT PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYLCISTEIN.

Also Published As

Publication number Publication date
EP2662077A1 (en) 2013-11-13
US20150313855A1 (en) 2015-11-05
US9561204B2 (en) 2017-02-07
US20130302259A1 (en) 2013-11-14
US8747894B2 (en) 2014-06-10
EP2662077B1 (en) 2017-03-01
US9427421B2 (en) 2016-08-30
US20160331710A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
US5629013A (en) Chewable calcium carbonate antacid tablet compositions
US9561204B2 (en) Effervescent compositions containing N-acetylcysteine
KR20100093105A (en) Dispersible tablet
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
KR101203186B1 (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
US20190216737A1 (en) Pediatric formulation
ES2928347T3 (en) DPP-IV inhibitor fast disintegrating tablet compositions with low mineral content
KR102397334B1 (en) two-component composition
EP2574333A1 (en) N-acetylcysteine effervescent tablet and its therapeutical applications
AU2013346766B2 (en) Effervescent tablet
ES2215025T3 (en) EFERVESCENT PHARMACEUTICAL FORMULATION, CONTAINING METAMIZOL.
JPS61280419A (en) Therapeutical tablet-form medicine
ES2694710T3 (en) Tablets comprising an agent that masks the taste
EP2905020A1 (en) Effervescent formulations comprising ibuprofen and N-acetylcystein
JP2005281324A (en) Amino sugar-containing preparation
JP2018076312A (en) Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components
JP6907486B2 (en) Solid formulation
RU2543322C1 (en) Pharmaceutical composition for treating hiv-infection, method for preparing and method of using
KR100904165B1 (en) Dispersible acetaminophen tablet and manufacturing process thereof
IT201900000268A1 (en) "COMPOSITIONS FOR THE TREATMENT OF THE CONSTIPATION"
Karemore et al. FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF AN ANTIDIABETIC DRUG
NZ243613A (en) Tablet comprising praziquantel, pyrantel pamoate and oxantel pamoate in synergistic proportions for treatment of nematode infestations
JP2016008208A (en) Method of stabilizing meclizine-containing pharmaceutical composition
JP2014139254A (en) Amino sugar-containing preparation
JPWO2014051025A1 (en) Anagliptin-containing solid preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALPEX PHARMA S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STROPPOLO, FEDERICO;GRANATA, GABRIELE;SHAHBAZ, ARDALAN;REEL/FRAME:032784/0949

Effective date: 20120507

AS Assignment

Owner name: ALPEX PHARMA S.A., SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THE NAME OF THE THIRD INVENTOR PREVIOUSLY RECORDED ON REEL 032784 FRAME 0949. ASSIGNOR(S) HEREBY CONFIRMS THE THE CORRECT NAME IS SHAHBAZ S. ARDALAN;ASSIGNORS:STROPPOLO, FEDERICO;GRANATA, GABRIELE;ARDALAN, SHAHBAZ S.;REEL/FRAME:033675/0763

Effective date: 20120507

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION